Acadia Pharmaceuticals Inc., of San Diego, appointed Paul Anderson to its scientific advisory board.
AtheroGenics Inc., of Atlanta, elected David Bearman to its board and to serve on its audit committee.
Avigen Inc., of Alameda, Calif., added Glenn Pierce as vice president, clinical development.
Ceregene Inc., of San Diego, appointed Raymond Bartus vice president of research and development.
Charles River Laboratories International Inc., of Wilmington, Mass., added Renita Johnson-Leva as director, quality assurance and regulatory affairs of its Biopharmaceutical Testing Division.
Corgentech Inc., of Palo Alto, Calif., appointed Lynn Seely vice president of clinical research.
Cryo-Cell International Inc., of Clearwater, Fla., appointed Jagdish Sheth to its board.
CV Therapeutics Inc., of Palo Alto, Calif., said Luiz Belardinelli, its vice president, drug research and pharmacological sciences, was named the first CV Therapeutics distinguished fellow of cardiovascular science.
Neurocrine Biosciences Inc., of San Diego, elected Thomas Mitchell to its board.
NuGen Technologies Inc., of San Carlos, Calif., appointed James Stanchfield vice president of commercial operations.
Oxford BioMedica plc, of Oxford, UK, appointed David Higgins vice president for business development at Oxford's San Diego subsidiary.
Pain Therapeutics Inc., of South San Francisco, added Peter Roddy as chief financial officer.
Protein Sciences Corp., of Meriden, Conn., elected Manon Cox chief operating officer.